Protein Drives Metabolic Liver Disease Independent of Diet
University of Utah researchers have identified the EFHD1 protein as a key driver of metabolic liver disease, independent of dietary fat intake. Blocking this protein in lab models showed potential for preventing liver injury, offering a new target for therapeutic drug development.
Why it matters
This discovery could lead to new treatments for obesity-related liver conditions that are not solely dependent on lifestyle changes, addressing a major global health challenge.
EFHD1 protein, which triggers an out-of-place antiviral immune response, could be a potential therapeutic target.
September 21, 2026 • By University of Utah
Study Identifies Potential Therapeutic Target Protein That Drives Metabolic Liver Disease Independent of Diet
Obesity-related metabolic liver disease affects hundreds of millions of people worldwide, but only some fraction of those livers develop scarring, become inflamed, and eventually fail. University of Utah researchers have identified a protein, EFHD1, that appears to drive that transition by triggering an out-of-place antiviral immune response.
They also demonstrated that blocking the protein can protect against liver injury in human cells and mouse models, even on a high-fat diet - paving the way for therapies to prevent liver damage.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in